


IN THE CLAIMS

Please amend the claims as follows:


Claim 1 (Currently Amended): Clopidogrel hydrobromide in the crystalline Form I characterized by an X-ray diffraction pattern with characteristic interplanar distances  $d$  of 4.0; 4.39 and 3.17 Å.



Claim 2 (Original): Clopidogrel hydrobromide in the crystalline Form I according to claim 1 characterized by interplanar distances  $d$  of 3.12; 6.99; 5.5; 4.29 and 3.65 Å.

Claim 3 (Currently Amended): Clopidogrel hydrobromide in the crystalline Form I according to ~~claims 1 or 2~~ claim 1 characterized by bands in the infrared spectra at 1743; 1421; 1237; 760 and 728  $\text{cm}^{-1}$ .

Claim 4 (Currently Amended): Clopidogrel hydrobromide in the crystalline Form II characterized by an X-ray diffraction pattern with characteristic interplanar distances  $d$  of 4.52; 3.83; 3.48 Å.



Claim 5 (Original): Clopidogrel hydrobromide in the crystalline Form I according to claim 4 characterized by interplanar distances  $d$  of 6.38; 2.76 and 3.23 .

Claim 6 (Currently Amended): Clopidogrel hydrobromide in the crystalline Form II according to ~~claims 4 or 5~~ claim 4 characterized by bands in the infrared spectra at 1754; 1436; 1317 and 1223  $\text{cm}^{-1}$ .

Claim 7 (Original): Clopidogrel hydrobromide of Form II with peaks ascertained by X-ray diffraction in the following  $2\theta$  positions: 7.796°; 15.380°; 18.389°; 19.369° and 23.895°.

Claim 8 (Currently Amended): A method of preparation of clopidogrel hydrobromide of the crystalline Form I according to ~~claims 1-3~~ claim 1 characterized in that clopidogrel base dissolved in toluene is precipitated with a concentrated solution of hydrobromic acid.

Claim 9 (Original): The method according to claim 8 characterized in that after precipitation, the resulting oily matter is mixed with toluene for a time necessary for formation of crystals.

Claim 10 (Original): The method according to claim 8 characterized in that a 48% solution of hydrobromic acid in water is added to a solution of 5 to 15% of the clopidogrel base in toluene, whereas the molar ratio of the clopidogrel base and hydrogen bromide is 1:0.9 to 1.5.

Claim 11 (Currently Amended): A method of preparation of clopidogrel hydrobromide of the crystalline Form II according to ~~claims 4-6~~ claim 4 characterized in that the clopidogrel base is dissolved in an organic solvent and precipitated with a solution of hydrobromic acid in toluene.

Claim 12 (Original): The method according to claim 11 characterized in that precipitation is performed at temperatures 0 to 30°C and growth crystals occurs at temperatures lower than 10°C.

Claim 13 (Original): The method according to claim 11 characterized in that a solution of the clopidogrel base having a concentration of 5 to 40 weight % is used and is precipitated with a solution of hydrogen bromide in toluene having a concentration of 5 to 15 weight %, whereas the molar ratio of the clopidogrel base and hydrogen bromide is 1:0.9 to 1.1.

Claim 14 (Currently Amended): A method of preparation of clopidogrel hydrobromide of crystalline Form II of claim 4 characterized in that clopidogrel base is dissolved in an organic solvent and precipitated with gaseous hydrogen bromide, and, optionally, the resulting clopidogrel hydrobromide is further dissolved and crystallized from a

solvent comprising a C<sub>1</sub>-C<sub>5</sub> alcohol or a mixture of a C<sub>1</sub>-C<sub>5</sub> alcohol with an ether, ester or ketone.

Claim 15 (Original): The method according to claim 14 characterized in that clopidogrel hydrobromide is precipitated from an organic solvent selected from the group of C<sub>6</sub>-C<sub>12</sub> aromatic hydrocarbons.

Claim 16 (Original): The method according to claim 14 characterized in that precipitation is carried out at a temperature of -15°C to 30°C and growth of crystals occurs at a temperature lower than 10°C.

Claim 17 (Original): The method according to claim 14 characterized in that a solution of the clopidogrel base having a concentration of 1 to 40% is used, the molar ratio of the clopidogrel base and hydrogen bromide being 1:0.9 to 1.1.

Claim 18 (Currently Amended): The method according to any of ~~claims 14-17~~ claim 17, characterized in that gaseous hydrogen bromide is introduced into a solution of the clopidogrel base having a concentration of 15 to 40%.

Claim 19 (Currently Amended): The method according to any of ~~claims 14-16~~ claim 14 characterized in that gaseous hydrogen bromide is introduced into a solution of the clopidogrel base having a concentration of 1 to 10% clopidogrel hydrobromide of Form III of claim 7, thus being precipitated, which is further crystallized from a C<sub>1</sub>-C<sub>5</sub> alcohol or a C<sub>1</sub>-C<sub>15</sub> alcohol in an admixture with an ether, ester or ketone.

Claim 20 (Original): The method according to claim 18 characterized in that clopidogrel hydrobromide of Form II is crystallized from a mixture of a C<sub>1</sub>-C<sub>5</sub> alcohol and an ether.

Claim 21 (Currently Amended): ~~Use of~~ The method of using clopidogrel hydrobromide of Form III according to claim 7 for the preparation of clopidogrel hydrobromide of Form II of claim 4, applicable as a pharmaceutical active substance.